On May 20, the Council for Innovation Promotion (C4IP) sent a letter addressed to the U.S. Senate Committee on the Judiciary one day before the committee held a hearing on competition and consumer pricing in the prescription drug market. C4IP’s letter pushes back against common myths about the impact of patents on drug prices, some of which were the focus of debate during the Judiciary Committee hearing this week, to better inform Congressional efforts on expanding access to medicines for American consumers.
Recent Posts
- Other Barks & Bites for Friday, April 4: CAFC Corrects Date of Public Accessibility in Trade Secret Appeal; Sixth Circuit Issues Divided Opinion in Data Privacy Appeal; and OpenAI Urges Broad Copyright Exception in UK
- Federal Circuit Tells Patent Applicant Expired Patents Don’t Get Provisional Rights Either
- Senate Judiciary Committee to Consider Bills Targeting Pharma Patents and Pricing
- USPTO Acting Director Expands on Reasoning for New Interim PTAB ‘Workload Management’ Process
- Strong IP Protections are the Key to Growing U.S. Manufacturing